Free Trial

Collegium Pharmaceutical (COLL) Competitors

Collegium Pharmaceutical logo
$31.57 +0.67 (+2.17%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$31.58 +0.00 (+0.02%)
As of 07/8/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

COLL vs. ACAD, MRUS, ACLX, SWTX, RNA, RARE, PTGX, AAPG, SRRK, and MLTX

Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include ACADIA Pharmaceuticals (ACAD), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

Collegium Pharmaceutical vs. Its Competitors

Collegium Pharmaceutical (NASDAQ:COLL) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 6 mentions for ACADIA Pharmaceuticals. Collegium Pharmaceutical's average media sentiment score of 0.88 beat ACADIA Pharmaceuticals' score of 0.78 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Collegium Pharmaceutical
5 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
ACADIA Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Collegium Pharmaceutical has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

ACADIA Pharmaceuticals has a net margin of 22.97% compared to Collegium Pharmaceutical's net margin of 6.61%. Collegium Pharmaceutical's return on equity of 99.08% beat ACADIA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical6.61% 99.08% 15.14%
ACADIA Pharmaceuticals 22.97%17.46%10.75%

ACADIA Pharmaceuticals has higher revenue and earnings than Collegium Pharmaceutical. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Collegium Pharmaceutical$631.45M1.61$69.19M$1.2225.88
ACADIA Pharmaceuticals$957.80M3.67$226.45M$1.3715.34

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 2.5% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Collegium Pharmaceutical presently has a consensus target price of $43.75, suggesting a potential upside of 38.58%. ACADIA Pharmaceuticals has a consensus target price of $27.88, suggesting a potential upside of 32.61%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
ACADIA Pharmaceuticals
0 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.71

Summary

ACADIA Pharmaceuticals beats Collegium Pharmaceutical on 9 of the 16 factors compared between the two stocks.

Get Collegium Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COLL vs. The Competition

MetricCollegium PharmaceuticalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$992.87M$2.39B$5.47B$8.95B
Dividend YieldN/A1.80%5.25%4.06%
P/E Ratio25.888.9827.0020.10
Price / Sales1.61729.50428.95120.24
Price / Cash2.50159.8036.8257.86
Price / Book4.454.517.985.56
Net Income$69.19M$31.26M$3.16B$248.40M
7 Day Performance3.47%3.57%2.39%4.67%
1 Month Performance3.71%1.28%2.18%6.64%
1 Year Performance-0.28%1.08%33.82%21.31%

Collegium Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COLL
Collegium Pharmaceutical
4.3568 of 5 stars
$31.57
+2.2%
$43.75
+38.6%
-1.0%$992.87M$631.45M25.88210Buyback Announcement
ACAD
ACADIA Pharmaceuticals
4.6689 of 5 stars
$21.57
-2.5%
$27.88
+29.2%
+28.8%$3.70B$957.80M15.74510
MRUS
Merus
2.0865 of 5 stars
$52.60
-0.7%
$84.64
+60.9%
-6.1%$3.67B$36.13M-12.8937Positive News
ACLX
Arcellx
2.2837 of 5 stars
$65.85
+0.8%
$111.23
+68.9%
+19.3%$3.60B$107.94M-22.0280
SWTX
SpringWorks Therapeutics
1.5381 of 5 stars
$46.99
+0.0%
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230
RNA
Avidity Biosciences
2.4635 of 5 stars
$28.40
-2.2%
$65.59
+130.9%
-24.3%$3.50B$10.90M-9.47190
RARE
Ultragenyx Pharmaceutical
4.0595 of 5 stars
$36.36
-0.4%
$87.00
+139.3%
-5.0%$3.45B$560.23M-6.181,294
PTGX
Protagonist Therapeutics
2.3364 of 5 stars
$55.27
-0.8%
$66.10
+19.6%
+43.3%$3.45B$434.43M73.69120
AAPG
Ascentage Pharma Group International
N/A$39.38
-0.6%
N/AN/A$3.45B$134.35M0.00600News Coverage
Positive News
SRRK
Scholar Rock
3.3041 of 5 stars
$35.42
-1.1%
$42.67
+20.5%
+335.1%$3.40B$33.19M-14.00140
MLTX
MoonLake Immunotherapeutics
1.9846 of 5 stars
$47.20
-0.7%
$74.50
+57.8%
+7.4%$3.04BN/A-20.522News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:COLL) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners